Policy

RAC Exploring Possibilities of In Utero Gene Therapy

Published in Gene Therapy Weekly, February 13th, 1995

Although neither the Recombinant DNA Advisory Committee (RAC) of the U.S. National Institutes of Health (NIH) nor the U.S. Food and Drug Administration (FDA) have received any proposals concerning in utero gene therapy, the RAC opened discussions on the ethics of such undertakings in December 1994.

The RAC decided to establish a working group on the subject, and its call for an initial exploration of the state of the subject at a December 1-2, 1994, meeting brought unexpected reports of progress in the area, together with the unsettling prospect of unintentional germ-line gene transfer.

Committee members expressed eagerness to confront the subject. ...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1995-02-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry